| Previous close | 1,724.25 |
| Open | 1,724.25 |
| Bid | 1,727.00 x N/A |
| Ask | 1,755.50 x N/A |
| Day's range | 1,724.25 - 1,724.25 |
| 52-week range | 1,705.00 - 2,798.00 |
| Volume | |
| Avg. volume | 15 |
| Market cap | 110.589B |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | 20.79 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with relapsed/refractory follicular lymphoma after two or more prior therapies.
- Investor's Business Daily
Genmab Takes The Next Step In Its 'Evolution' With A $1.8 Billion Takeover
Genmab stock slumped Wednesday after the Danish biotech announced it will buy privately held ProfoundBio for $1.8 billion.
- Insider Monkey
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]
© 2024 Yahoo. All rights reserved.